Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Dow
Harvard Business School
Merck
McKinsey

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

ERAVACYCLINE DIHYDROCHLORIDE - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for eravacycline dihydrochloride and what is the scope of patent protection?

Eravacycline dihydrochloride is the generic ingredient in one branded drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eravacycline dihydrochloride has sixty-four patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for ERAVACYCLINE DIHYDROCHLORIDE
International Patents:64
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 10
DailyMed Link:ERAVACYCLINE DIHYDROCHLORIDE at DailyMed
Recent Clinical Trials for ERAVACYCLINE DIHYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tetraphase Pharmaceuticals, Inc.Phase 3
Tetraphase Pharmaceuticals, Inc.Phase 1
Department of Health and Human ServicesPhase 1

See all ERAVACYCLINE DIHYDROCHLORIDE clinical trials

US Patents and Regulatory Information for ERAVACYCLINE DIHYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ERAVACYCLINE DIHYDROCHLORIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2323972 LUC00107 Luxembourg   Start Trial PRODUCT NAME: XERAVA - ERAVACYLINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
2323972 PA2019009 Lithuania   Start Trial PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920
2323972 CA 2019 00009 Denmark   Start Trial PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
2323972 122019000024 Germany   Start Trial PRODUCT NAME: ERAVACYCLINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920
2323972 12/2019 Austria   Start Trial PRODUCT NAME: ERAVACYCLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 (MITTEILUNG) 20180924
2323972 CR 2019 00009 Denmark   Start Trial PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Dow
Colorcon
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.